Comparative Binding Effects of Aspirin and Anti-Inflammatory Cu Complex in the Active Site of LOX-1

Coordination-induced emission enhancement in copper(I) iodide coordination polymers supported by 2-(alkylsulfanyl)pyrimidines

First examples of copper(i) complexes with 2-(alkylsulfanyl)pyrimidine ligands have been synthesized. Reactions of copper(i) iodide with 2-(methylsulfanyl)pyrimidine (L1) in various metal-to-ligand molar ratios in MeCN afford a ladder-type coordination polymer [Cu2L1I2]n with polymeric chains built from double-stranded (Cu2I2)n ribbons supported on both sides by μ2-N,S-L1 molecules. Although the second ligand, 2-(ethylsulfanyl)pyrimidine (L2), differs from L1 only by a methylene group, its reactions with copper(i) iodide in MeCN yield not only a congenerous coordination polymer, [Cu2L2I2]n, but also [CuL2I]n, in which a similar (Cu2I2)n ribbon is decorated by N-monodentate L2 molecules. Absorption spectra of all compounds represent an interplay of metal + iodine-to-ligand charge transfer (XMLCT) and ligand-centered (LC) and cluster-centered (CC) transitions, while the emission occurs from the excited states of XMLCT nature. The luminescence of [Cu2L1I2]n and [Cu2L2I2]n is blue-shifted and greatly enhanced in comparison with that of [CuL2I]n (quantum yields: 89% and 68% for [Cu2L1I2]n and [Cu2L2I2]nvs. 23% for [CuL2I]n at 77 K), which can be associated with a more rigid μ2-N,S coordination of 2-(alkylsulfanyl)pyrimidine ligands in [Cu2L1I2]n and [Cu2L2I2]n leading to a less distorted T1 state.

Advances in NMR Methods To Map Allosteric Sites: From Models to Translation

The last five years have witnessed major developments in the understanding of the allosteric phenomenon, broadly defined as coupling between remote molecular sites. Such advances have been driven not only by new theoretical models and pharmacological applications of allostery, but also by progress in the experimental approaches designed to map allosteric sites and transitions. Among these techniques, NMR spectroscopy has played a major role given its unique near-atomic resolution and sensitivity to the dynamics that underlie allosteric couplings. Here, we highlight recent progress in the NMR methods tailored to investigate allostery with the goal of offering an overview of which NMR approaches are best suited for which allosterically relevant questions. The picture of the allosteric "NMR toolbox" is provided starting from one of the simplest models of allostery (i.e., the four-state thermodynamic cycle) and continuing to more complex multistate mechanisms. We also review how such an "NMR toolbox" has assisted the elucidation of the allosteric molecular basis for disease-related mutations and the discovery of novel leads for allosteric drugs. From this overview, it is clear that NMR plays a central role not only in experimentally validating transformative theories of allostery, but also in tapping the full translational potential of allosteric systems.

Manganese-mefenamic acid complexes exhibit high lipoxygenase inhibitory activity

The coordination of non-steroidal anti-inflammatory drugs (NSAIDs) to metal ions could improve the pharmaceutical efficacy of NSAIDs due to the unique characteristics of metal complexes.

The lectin-like oxidized low-density lipoprotein receptor-1 as therapeutic target for atherosclerosis, inflammatory conditions and longevity

INTRODUCTION

The lectin-like oxidized LDL receptor-1 (LOX-1) is a scavenger receptor and is regarded as a central element in the initiation of endothelial dysfunction and its further progression to atherosclerosis. Increasing numbers of studies suggest that therapeutic strategies to modulate LOX-1 will have a broad spectrum of applications ranging from cardiovascular diseases to longevity.

AREAS COVERED

The dual role of LOX-1 as a culprit molecule in the process of atherosclerosis and as a danger signal in various tissues is introduced. The structure of the receptor, its ligands and its modulation by known drugs, by natural products (e.g., statins, imipramine, salicylate-based drugs, procyanidins, curcumin) and by new strategies (antisenseRNA, miRNA, pyrrole-imidazol-polyamides, LOX-1 antibodies, lipid apheresis) are described.

EXPERT OPINION

Therapeutic approaches via transcript regulation, allowing a modulation of LOX-1, may be an easier and safer strategy than a blockade of the receptor. Considering the wide distribution of LOX-1 on different tissues, research on the mechanisms of LOX-1 modulation by drugs and natural products applying "omic"-technologies will not only allow a better understanding of the role of LOX-1 in the processes of atherosclerosis, inflammation and longevity but also support the development of specific LOX-1 modulators, avoiding the initiation of molecular mechanisms which lead to adverse events.